Using Nicotinamide Riboside to Prevent Heart Problems in Breast Cancer Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of nicotinamide riboside in preventing cardiac dysfunction in women with metastatic breast cancer who are undergoing anthracycline chemotherapy. It is a prospective, randomized, double-blind, and placebo-controlled study involving 60 participants. The primary outcome will be measured by changes in left ventricular ejection fraction using cardiac MRI, while secondary outcomes will include various cardiac biomarkers and assessments of functional capacity and quality of life. Participants will be monitored at baseline, 3 months, and potentially 6 months, depending on their treatment duration.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy
* Eastern Cooperative Oncology Group performance status 0-2

Exclusion Criteria

* Age \<18 years
* Acute myocardial infarction within the last three months
* Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer
* Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers
* Life expectancy \< 6 months
* Known allergy to any of the components in the Nicotinamide Riboside (Niagen®) tablet
* Contraindications or inability to undergo CMR examination

Where it's running

• Akershus University Hospital
  Lørenskog, Akershus, Norway Recruiting

Study contacts

• Principal investigator: Torbjørn Omland, MD, PhD — University Hospital, Akershus
• Study coordinator: Torbjørn Omland, MD, PhD
• Email: torbjorn.omland@medisin.uio.no
• Phone: +47 40107050

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Sacubitril/Valsartan to prevent heart damage in breast cancer treatment

  This study is testing if the medication Sacubitril/Valsartan can help protect the hearts of women undergoing treatment for breast cancer from damage.

  Recruiting at 3 sites Phase 4 Silesian Centre for Heart Diseases · Opole, Opole Voivodeship and 3 other locations · NCT05465031

• Exercise and fitness program for breast cancer survivors to improve heart health

  This study tests whether a special exercise and yoga program can help breast cancer survivors over 60 improve their heart health and physical fitness after treatment.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06595147

• 3D Heart Strain to Detect Early Cardiotoxicity in Cancer Therapy

  This study tests whether 3D echocardiography can detect early heart damage from cancer treatments like anthracyclines or HER2-targeted therapy better than standard 2D methods.

  Recruiting Region Skane · Lund, Skåne County · NCT07916337

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer

  This study tests whether heart changes seen on ultrasound and blood biomarkers can detect early heart problems in women receiving standard chemotherapy and anti-HER2 therapy for early breast cancer.

  Recruiting Gazi University · Ankara, Ankara · NCT07588425

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.